Browse EX-10 agreements

VISIONWAVE HOLDINGS, INC.

300 Delaware Avenue, Suite 210 #301

Wilmington, Delaware 19801

** **

July 28, 2026

Matania (Mati) Moskovich

c/o CMFBM - Hareches 21, Modiin, Israel

C.M. Composite Materials Ltd.

Hareches 21, Modiin, Israel

Re: Side Letter — Extension of Belrise Long-Stop Date and Outside Closing Date under the Investment and Share Purchase Agreement, dated as of February 20, 2026, as amended

Ladies and Gentlemen:

…

RELEASE AND SEPARATION AGREEMENT

This Release and Separation Agreement (this “Agreement”) is entered into as of July 29, 2026 (the “Effective Date”), by and between Mangoceuticals, Inc., a Texas corporation (the “Company”), and Jacob Cohen (“Executive”).

RECITALS

WHEREAS, Executive is employed as the Chief Executive Officer of the Company pursuant to that certain Amended and Restated Executive Employment Agreement dated December 13, 2024 (the “Employment Agreement”); and

WHEREAS, the Company is entering into a business combination (the “Transaction”) with Nuclea Energy Inc. (“Nuclea”), pursuant to a Business Combination Agreement executed contemporaneously herewith (the “BCA”), which, upon Completion shall constitute a Change of Control under the Employment Agreement; and

WHEREAS, in connection with the Transaction, Upon the Closing, Executive will transition from his position as Chief Executive Officer to the position of President of the Company;

…

EXECUTION VERSION

SEPARATION AGREEMENT AND
GENERAL RELEASE OF CLAIMS

This Separation Agreement and General Release of Claims (this “Agreement”) is entered into as of July 29, 2026 by and between Wayne D. Thorsen (“Executive”) and Sirius XM Holdings Inc., a Delaware corporation (together with its subsidiaries and affiliates, including Sirius XM Radio LLC, the “Company”).

WHEREAS, Executive is currently employed by the Company as Executive Vice President and Chief Operating Officer pursuant to that certain Employment Agreement between Executive and Sirius XM Radio LLC, dated as of December 5, 2024 (the “Employment Agreement”);

WHEREAS, Executive will cease to be the Company’s Executive Vice President and Chief Operating Officer and an employee of the Company on July 31, 2026 (the “Separation Date”);

WHEREAS, Executive and the Company wish to ensure the orderly transition of Executive’s duties and responsibilities in connection with his separation from employment with the Company; and

…

** **

Execution Version

** **

WAIVER, CONSENT AND AMENDMENT NO. 8 to CREDIT AGREEMENT

This WAIVER, CONSENT AND AMENDMENT NO. 8 TO CREDIT AGREEMENT (this “Agreement”) is entered into as of July 27, 2026, by and among T1 G1 Dallas Solar Module LLC, a Texas limited liability company (the “Borrower”), the lenders party hereto constituting the Required Lenders under the Credit Agreement (defined below) (collectively, the “Required Lenders”), HSBC Bank USA, N.A., a national banking association, as administrative agent for the Lenders (in such capacity, together with any successor administrative agent appointed pursuant to the Loan Documents, the “Administrative Agent”), and HSBC Bank USA, N.A., a national banking association, as collateral agent for the Secured Parties (in such capacity, together with any successor collateral agent appointed pursuant to the Loan Documents, the “Collateral Agent,” and together with the Borrower, the Required Lenders, and the Administrative Agent, collectively, the “Parties”).

** **

W I T N E S S E T H

** **

…

BRAVEHEART BIO, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

ThepurposeofthisNon-Employee DirectorCompensationPolicy (the “Policy”) of Braveheart Bio, Inc., a Delaware corporation (the“Company”),isto provideatotalcompensationpackagethatenablestheCompany toattractandretain,onalong-termbasis,high-caliberdirectorswhoarenotemployeesorofficersoftheCompany orits subsidiaries (“Outside Directors”). This Policy will become effective as of the effective time of the registration statement for the Company’s initial public offering of its equity securities (the “Effective Date”). Infurtherance ofthepurpose statedabove,allOutside Directorsshallbe paid compensation for services provided to theCompanyas Outside Directors as set forth below:

Cash Retainers

…

BRAVEHEART BIO, INC.

INDEMNIFICATION AGREEMENT

(For Directors of a Delaware Corporation)

This Indemnification Agreement (“Agreement”) is made as of [●] by and between Braveheart Bio, Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;

WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;

WHEREAS, the Certificate of Incorporation (as amended and in effect from time to time, the “Charter”) and the Bylaws (as amended and in effect from time to time, the “Bylaws”) of the Company require indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”);

…

BRAVEHEART BIO, INC.

2026 EMPLOYEE STOCK PURCHASE PLAN

The purpose of the Braveheart Bio, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Braveheart Bio, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.0001 per share (“Stock”). 894,100 shares of Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2027 and each January 1 thereafter until the Plan terminates pursuant to Section 20, the number of shares of Stock reserved and available for issuance under the Plan shall automatically be cumulatively increased by the least of (i) 894,100 shares of Stock, (ii) 1% of the number of Outstanding Shares on the immediately preceding December 31, and (iii) such number of shares of Stock as determined by the Administrator (as defined in Section 1).

…

BRAVEHEART BIO, INC.

2026 EXECUTIVE SEVERANCE AND CHANGE IN CONTROL PLAN AND SUMMARY PLAN DESCRIPTION

1.    Introduction and Purpose

This document serves as the Plan document and Summary Plan Description (“SPD”) for the severance pay and benefits provided under the Braveheart Bio, Inc. 2026 Executive Severance and Change in Control Plan (the “Plan”). Braveheart Bio, Inc., a Delaware corporation (including its successors, the “Company”), considers it essential to foster the continuous employment of key management personnel. The Company acknowledges the possibility of an involuntary termination of employment exists and that such possibility, and the uncertainty and questions that it may raise among management, may result in the departure or distraction of management personnel to the detriment of the Company.

…

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made between Braveheart Bio, Inc., a Delaware corporation (the “Company”), and [NAME] (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “EffectiveDate”). Except with respect to the Restrictive Covenants Agreement, the Equity Documents, the Executive Severance Plan (each of the foregoing, as defined below), the Indemnification Agreement between the Executive and the Company dated as of [DATE] (the “IndemnificationAgreement”), and the Participation Agreement dated of even date herewith between the Executive and the Company (the “Participation Agreement”), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated [DATE] (the “Prior Agreement”), and (ii) any other offer lette

…

BRAVEHEART BIO, INC.

2026 STOCK OPTION AND INCENTIVE PLAN

SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Braveheart Bio, Inc. 2026 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Braveheart Bio, Inc. (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company or one of its Affiliates.

The following terms shall be defined as set forth below:

“Act”means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder.

…

Dated 12 MAY 2026

CRH Group Management Limited
and

Aylwyn Bryan

_________________________________________________

GROUP CHIEF FINANCIAL OFFICER SERVICE AGREEMENT

_________________________________________________

1

---

This Agreement is made on May 12, 2026 between

(1)    CRH Group Management Limited incorporated in the Ireland whose registered office is at 42 Fitzwilliam Square, Dublin 2 (the “Company”); and

(2)    Aylwyn Bryan (the “Executive”).

This Agreement records the terms on which the Executive will serve the Group as its Group Chief Financial Officer.

1.    Interpretation

In this Agreement (and any schedules to it):

“Associated Company” means a subsidiary undertaking or holding undertaking of the Company, within the meaning of section 275 of the Companies Act 2014, or any subsidiary undertaking of such a holding undertaking, and any undertaking that the Board may determine for the purposes of this Agreement from time to time;

…

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of July 24, 2026, between NanoViricides, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below) as to the Shares (as defined below), the Warrants (as defined below) the Pre-Funded Warrants (as defined below) and the Warrant Shares (as defined below), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

…